|
Implant Sciences Adds Printing Capability to QS-H150 Explosives Trace Detector
WILMINGTON, MA, Apr 17, 2012 (MARKETWIRE via COMTEX) --
Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a
high technology supplier of systems and sensors for homeland security
and defense markets, today announced a key product enhancement for
its Quantum Sniffer(TM) QS-H150 handheld explosives trace detectors.
Using the QS-H150 Printing Kit, users will be able to print detection
results, creating a permanent record of the explosives screening
activity.
Available for purchase now, the kit includes a small, portable,
thermal printer, an interface cable, and paper. The system can be
configured in either automatic or manual printing modes. Each
printout provides complete sample information including date and
time, substances detected, system performance parameters, and more.
"The ability to print detection results increases the usefulness of
the QS-H150 in several market segments, including checkpoint
screening and air cargo," stated Implant Sciences President and CEO
Glenn D. Bolduc. "Implant Sciences' commitment to satisfying customer
needs has helped make our products the choice of security
professionals around the world."
About the Quantum Sniffer(TM) QS-H150
The QS-H150 is a handheld
explosives trace detector that uses Ion Mobility Spectrometry (IMS)
to rapidly detect and identify trace amounts of a wide variety of
military, commercial, and homemade explosives. The QS-H150 uses no
radioactive materials and features a low-maintenance design that is
self-calibrating and self-clearing, providing very high levels of
operational availability.
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated
sensors and systems for Security, Safety, and Defense (SS&D) markets.
The Company has developed proprietary technologies used in its
commercial explosive and narcotics trace detection systems which ship
to a growing number of locations domestically and internationally.
Implant Sciences' QS-H150 portable explosives trace detector has
received Qualified Anti-Terrorism Technology Designation and the
Company's QS-B220 bench-top explosives and narcotics trace detector
has received a Developmental Testing & Evaluation (DT&E) Designation
by the U.S. Department of Homeland Security under the Support
Anti-terrorism by Fostering Effective Technology Act of 2002 (the
SAFETY Act). For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com
Safe Harbor Statement
This press release may contain certain "forward-looking statements,"
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Such statements are based on management's current
expectations and are subject to risks and uncertainties that could
cause the Company's actual results to differ materially from the
forward-looking statements. Such risks and uncertainties include, but
are not limited to, the risks that our explosives detection products
and technologies (including any new products we may develop) may not
be accepted by the Transportation Security Administration or by other
U.S. or foreign government and law enforcement agencies or commercial
consumers of security products; economic, political and other risks
associated with international sales and operations could adversely
affect our sales; our business is subject to intense competition and
rapid technological change; the risks that our markets are subject to
technological change and that our success depends on our ability to
develop and introduce new products; that our success depends on our
ability to obtain new patents and operate without infringing on the
proprietary rights of others; that we may not obtain the patents we
have applied for; that the validity and breadth of claims in
technology patents involve complex legal and factual questions and,
therefore, may be highly uncertain; that any patents we may obtain
may be may be challenged and subsequently invalidated, that we may
incur substantial costs in asserting our patent rights; and other
risks and uncertainties described in our filings with the Securities
and Exchange Commission, including its most recent Forms 10-K, 10-Q
and 8-K. Such statements are based on management's current
expectations and assumptions which could differ materially from the
forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
SOURCE: Implant Sciences Corporation
http://www2.marketwire.com/mw/emailprcntct?id=5C04616F5B3D00B4
http://www2.marketwire.com/mw/emailprcntct?id=644A4F866E6C9BD1
[ Back To TMCnet.com's Homepage ]
|
Call Center/CRM
Info Tech 
IP Communications 
Mobile 
Green 
Satellite 
Robotics 
Internet Telephony Magazine
Click here to read latest issue
CUSTOMER 
Cloud Computing Magazine
Click here to read latest issue
M2M Evolution Magazine
